Arcturus therapeutics announces approval from vietnam ministry of health to proceed into phase 3b study for arct-154, a next generation starr™ mrna vaccine targeting sars-cov-2 delta variant and other variants of concern

San diego--(business wire)---- $arct #clinicaltrial--arcturus therapeutics holdings inc. (the “company”, “arcturus”, nasdaq: arct), a leading clinical-stage messenger rna medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the vietnam ministry of health has approved initiation of the phase 3b part of the placebo-controlled, observer-blind phase 1/2/3 clinical trial of arct-154 self-replicating rna vacc
ARCT Ratings Summary
ARCT Quant Ranking